Gleason 6 Prostate Cancer is not Deadly

Tumor samples from a prostate biopsy are graded (Gleason score) which is an indication of a tumor’s aggressiveness. The tumor grade reflects how far the cancer cells deviate from normal healthy cells. Gleason 6 cancer looks almost like normal prostate gland tissue while higher Gleason scores are indicative of more serious cancers. The Prostate Cancer Research Institute (PCRI) recently published an e mail video from Dr. Mark Scholz stating that in a survey of 26,000 men, it was concluded that surgically-proven Gleason 6 prostate cancer does not metastasize. Men diagnosed with grade 6 cancer should be followed by “watching” and not “treating”. In this study, 22 men with positive nodes were regraded to Gleason 7 or higher. If this study is applicable to your case, please be advised to discuss this video and its conclusions with your personal urologist or oncologist.

Message to Men; Please Circulate

Blogger Dr. Bjarne (B.J.) Gabrielsen at Boca Grande Lighthouse, Charlotte Harbor, Punta Gorda, Southwest Florida Gulf Coast

I am a prostate cancer survivor since 1995. If you know of any men in your life who may have an interest in prostate cancer at any stage of disease, please inform them of this website,, .com, .org or .info. As blogs are posted, readers can receive them automatically by e mail by simply inserting their e mail address in the indicated space on the right side of the home page. Posts focus on all aspects of prostate cancer as well as encouraging commentaries which we all need at one time or another. Comments on any specific post are always welcome. Remember, as men, we are all in this together and God desires to play a central role in our lives. While I am not a medical doctor, I received my doctorate in organic chemistry at the State University of New York – Stony Brook. My career was evenly distributed between academia (Wagner College, NY and the University of Florida, Gainesville, FL) and government (NCI). I retired from the National Cancer Institute (NCI), National Institutes of Health (NIH) as Senior Advisor in antiviral and antitumor Drug Discovery and Development.

Prostate Cancer Foundation (PCF) 2019 Guide

Every year, the PCF publishes an electronic guide providing information on all aspects of prostate cancer. The chapters covered are as follows.

  1. General information including diagnosis, symptoms, risk factors, and medical basics.
  2. Information for the newly diagnosed, including detection, diagnosis and treatment selection.
  3. Treatment options for localized or locally advanced prostate cancer. These include active surveillance, surgery, various radiation modalities, and other experimental therapies for localized prostate cancer.
  4. Living with and after prostate cancer including sections on quality of life, recurrence, urinary, bowel and sexual function, diet, exercise and lifestyle changes.
  5. What to do if one’s PSA starts to rise. Topics include local treatments for recurrent cancer, therapies for advanced recurrent or metastatic cancer, hormone-resistant cancer, non-hormonal therapy options and side effects from various treatments for advanced prostate cancer.
  6. Cutting edge developments in prostate cancer research including precision medicine, PARP inhibitors, immune checkpoint inhibitors, CAR T cells and vaccines.
  7. Information for families of prostate cancer patients including future risk, genetic testing and screening and prevention.
  8. Here is a link to the most recent edition of the annual PCF prostate cancer guide.